Q-omics provides the consensus-scored SEC24A profile across patient tissues and cancer cell-line models. SEC24A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SEC24A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SEC24A protein abundance shows 25,781 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, KIRC, and GBM as cancer lineages where SEC24A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC24A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC24A survival associations across molecular data types. SEC24A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC24A RNA expression–survival associations across cancer types. High SEC24A expression shows unfavorable associations in CESC, LUSC, KICH, UVM, KIRP and STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SEC24A RNA expression.
This table summarizes SEC24A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEC24A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC24A shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, BLCA, BRCA and HNSC. The KIRC box plot shows higher SEC24A RNA expression in tumor versus normal tissue (log2 FC = +0.881, t-test p < 0.001).
This table shows molecular features associated with SEC24A in patient tissues and cancer cell lines. In patient samples, SEC24A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC24A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
